There are now European platforms for seeking early scientific advice with multiple payer organisatio...
Read moreThe aim of MAPPs is to enable quicker access for patients whilst providing adequate and evolving evi...
Read moreBased on the current clinical data, the PCSK9 inhibitors are a vital new treatment option for patien...
Read moreIt is the responsibility of CCGs to manage their local drug budgets
Read moreThis article contains official prices at the ex-manufacturer, wholesaler and pharmacy selling price ...
Read moreThe proposal states that the CDF should become a "managed access" fund for new cancer dugs, with cle...
Read morePharmaceutical companies are now launching curative treatments, in addition to drugs which only mana...
Read moreNHS England have recently proposed that NICE should take a more direct role in determining which pro...
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read more